Inventor

Sean C. Turner

Inventor

Mannheim, DE

Overview

2000–2020

Patent span

Chemistry

Primary field (CPC C)

Patents· 54 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary

C07DHeterocyclic compounds38%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations34%

A61KPreparations for medical, dental or toiletry purposes11%

C07CAcyclic or carbocyclic compounds5%

A63FCard, board, or roulette games2%

C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients2%

C08LCompositions of macromolecular compounds2%

G03FPhotomechanical production of textured or patterned surfaces, e.g. for printing, for processing of semiconductor devices2%

G06FElectric digital data processing2%

G06QInformation and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes2%

PatentTitleYear

10,556,907Fused heterocyclic compounds as S1P modulators2020 10,486,069Ranking of user-generated game play advice2019 10,100,048Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors2018 9,879,033'Modulators of 5-HT receptors and methods of use thereof'2018 9,856,234'Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors'2018 9,790,203'Inhibitor compounds of phosphodiesterase type 10A'2017 9,657,034'Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors'2017 9,540,370'Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors'2017 9,273,068'Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A'2016 9,266,855'Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors'2016 9,238,619'Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy'2016 9,187,483'Modulators of 5-HT receptors and methods of use thereof'2015 9,163,007'5-substituted indazoles as kinase inhibitors'2015 9,126,116'Ranking of user-generated game play advice'2015 9,108,108'Real-time, contextual display of ranked, user-generated game play advice'2015 9,090,592'Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors'2015 8,969,552'Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2015 8,877,794'Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy'2014 8,846,951'Modulators of 5-HT receptors and methods of use thereof'2014 8,648,069'5-substituted indazoles as kinase inhibitors'2014 8,642,642'Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor'2014 8,642,598'Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors'2014 8,507,469'Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor'2013 8,497,273'Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor'2013 8,492,540'1,2,4,-triazin-3,5-dione compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2013 8,486,984'Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2013 8,476,275'N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor'2013 8,470,810'Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2013 8,455,648'1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3)'2013 8,440,694'Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor'2013 8,383,641'Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2013 8,318,793'Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors'2012 8,293,913'Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor'2012 8,247,413'Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor'2012 8,242,102'Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor'2012 8,232,426'Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2012 8,101,754'Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2012 7,994,160'Pyridazine compounds as glycogen synthase kinase 3 inhibitors'2011 7,875,627'Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof'2011 7,851,463'Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2010 7,834,048'Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2010 7,790,727'Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor'2010 7,759,397'6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor'2010 7,348,343'Amides useful for treating pain'2008 7,335,678'Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor'2008 7,320,979'N-[(piperazinyl)hetaryl]arylsulfonamide compounds'2008 7,129,235'Amides useful for treating pain'2006 7,074,805'Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor'2006 6,933,311'Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor'2005 6,551,761'Photoactivatable nitrogen-containing bases based on -ammonium ketones, iminium ketones or amidinium ketones and aryl borates'2003 6,489,374'Photoactivatable bases containing nitrogen'2002 6,410,628'Photoactivatable nitrogen-containing bases based on alpha-amino ketones'2002 6,277,986'Photoactivatable nitrogen-containing bases based on .alpha.-amino ketones'2001 6,087,070'Photoactivatable nitrogen-containing bases based on .alpha.-amino alkenes'2000

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2000–2002Based in Berkeley, CA, US· patent location history

2002–2012Based in Evanston, IL, US· patent location history

2006–2018Based in Mannheim, DE· patent location history

2008–2016Patents assigned to ABBOTT GMBH & CO KG (21)· patent assignee history

2012–2015Patents assigned to DRESCHER KARLA (14)· patent assignee history

2012–2015Patents assigned to HAUPT ANDREAS (14)· patent assignee history

2012–2015Patents assigned to UNGER LILIANE (14)· patent assignee history

2012–2020Based in Ludwigshafen, DE· patent location history

2014–2020Patents assigned to ABBVIE DEUTSCHLAND (17)· patent assignee history

2016–2017Based in Wiesbaden, DE· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
ABBOTT GMBH & CO KG	21	2008–2016
ABBVIE DEUTSCHLAND	17	2014–2020
DRESCHER KARLA	14	2012–2015
HAUPT ANDREAS	14	2012–2015
UNGER LILIANE	14	2012–2015

Locations

Location	Patents	Span
Mannheim, DE	26	2006–2018
Ludwigshafen, DE	14	2012–2020
Evanston, Illinois, US	6	2002–2012
Berkeley, California, US	3	2000–2002
Wiesbaden, DE	2	2016–2017